Citations

Clear

410 citation(s) found for "Shu, Yu".

Comparison of the real‐world effectiveness of vertical versus lateral functional hemispherotomy techniques for pediatric drug‐resistant epilepsy: A post hoc analysis of the HOPS study
Fallah, Aria , Lewis, Evan , Ibrahim, George M. , Tseng, Chi‐Hong , Harris, William B., Chen, Jia‐Shu , Lin, Kao‐Min, Cai, Lixin , Liu, Qingzhu , Lin, Jiuluan , Mathern, Gary W. , Smyth, Matthew D. , O’Neill, Brent R., Dudley, Roy , Ragheb, John , Bhatia, Sanjiv, Delev, Daniel , Ramantani, Georgia , Zentner, Josef , Dorfer, Christian , Feucht, Martha , Czech, Thomas , Bollo, Robert J. , Issabekov, Galymzhan , Zhu, Hongwei , Connolly, Mary , Steinbok, Paul , Zhang, Kai , Weiner, Howard L. , Lapalme‐Remis, Samuel , Tripathi, Manjari , Chandra, P. Sarat , Hader, Walter , Wang, Feng‐Peng , Champagne, Pierre‐Olivier , Brunette‐Clément, Tristan , Budke, Marcelo , Pérez-Jiménez, María Ángeles, Raftopoulos, Christian , Finet, Patrice, Michel, Pauline, Schaller, Karl , Malone, Christian Cantillano, Pociecha, Juan , Chamorro, Noelia, Muro, Valeria L., Lehe, Marec von , Vieker, Silvia, Oluigbo, Chima , Gaillard, William D. , Al‐Khateeb, Mashael, Alotaibi, Faisal , Krayenbühl, Niklaus , Bolton, Jeffrey , Weil, Alexander G. , Cai, Li-Xin , Ramantani, Georgia , Dorfer, Christian , Feucht, Martha , Wong-Kisiel, Lily, Tripathi, Manjari , Sarat Chandra, Poodipedi , von Lehe, Marec , Gaillard, William D , Weil, Alexander G , Fallah, Aria , Chen, Jia-Shu , Oluigbo, Chima O , Kola, Olivia , Zhou, Wen-Jing , Wang, Anthony , Zhang, Jianguo , Hidalgo, Eveline Teresa , Wong‐Kisiel, Lily C. , Wang, Feng‐Peng, Yao, Yi , Guo, Qiang , Li, Shao‐Chun, Stienen, Martin Nikolaus , Baro, Valentina , Pearl, Phillip L.

Mayo Clinic

Epilepsia | September 12, 2021 | Volume: 62 | Issue: 11 | Pages: 2707-2718

10.1111/epi.17021 | PMID 34510448 Get It

AbstractObjectiveThis study was undertaken to determine whether the vertical parasagittal approach or the lateral peri‐insular/peri‐Sylvian approach to hemispheric surgery is the superior technique in achieving long‐term seizure freedom.MethodsWe conducted a post hoc subgroup analysis of the HOPS (Hemispheric Surgery Outcome Prediction Scale) study, an international, multicenter, retrospective cohort study that identified predictors of seizure freedom through logistic regression modeling. Only patients undergoing vertical parasagittal, lateral peri‐insular/peri‐Sylvian, or lateral trans‐Sylvian hemispherotomy were included in this post hoc analysis. Differences in seizure freedom rates were assessed using a time‐to‐event method and calculated using the Kaplan–Meier survival method.ResultsData for 672 participants across 23 centers were collected on the specific hemispherotomy approach. Of these, 72 (10.7%) underwent vertical parasagittal hemispherotomy and 600 (89.3%) underwent lateral peri‐insular/peri‐Sylvian or trans‐Sylvian hemispherotomy. Seizure freedom was obtained in 62.4% (95% confidence interval [CI] = 53.5%–70.2%) of the entire cohort at 10‐year follow‐up. Seizure freedom was 88.8% (95% CI = 78.9%–94.3%) at 1‐year follow‐up and persisted at 85.5% (95% CI = 74.7%–92.0%) across 5‐ and 10‐year follow‐up in the vertical subgroup. In contrast, seizure freedom decreased from 89.2% (95% CI = 86.3%–91.5%) at 1‐year to 72.1% (95% CI = 66.9%–76.7%) at 5‐year to 57.2% (95% CI = 46.6%–66.4%) at 10‐year follow‐up for the lateral subgroup. Log‐rank test found that vertical hemispherotomy was associated with durable seizure‐free progression compared to the lateral approach (p = .01). Patients undergoing the lateral hemispherotomy technique had a shorter time‐to‐seizure recurrence (hazard ratio = 2.56, 95% CI = 1.08–6.04, p = .03) and increased seizure recurrence odds (odds ratio = 3.67, 95% CI = 1.05–12.86, p = .04) compared to those undergoing the vertical hemispherotomy technique.SignificanceThis pilot study demonstrated more durable seizure freedom of the vertical technique compared to lateral hemispherotomy techniques. Further studies, such as prospective expertise‐based observational studies or a randomized clinical trial, are required to determine whether a vertical approach to hemispheric surgery provides superior long‐term seizure outcomes.
Integrating Genome and Methylome Data to Identify Candidate DNA Methylation Biomarkers for Pancreatic Cancer Risk
Zhu, Jingjing , Yang, Yaohua , Kisiel, John B. , Michaud, Dominique S. , Shu, Xiao-Ou , Liu, Duo , Li, Bingshan , Tao, Ran , Wu, Lang , Mahoney, Douglas W. , Shu, Xiao-Ou , Cai, Qiuyin , Zheng, Wei , Kisiel, John B , Michaud, Dominique S , Guo, Xingyi , Taylor, William R. , Shu, Xiao‐Ou , Cai, Qiuyin , Zheng, Wei , Long, Jirong , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 9, 2021 | Volume: 30 | Issue: 11 | Pages: 2079-2087

10.1158/1055-9965.epi-21-0400 | PMID 34497089 Get It

AbstractBackground:The role of methylation in pancreatic cancer risk remains unclear. We integrated genome and methylome data to identify CpG sites (CpG) with the genetically predicted methylation to be associated with pancreatic cancer risk. We also studied gene expression to understand the identified associations.Methods:Using genetic data and white blood cell methylation data from 1,595 subjects of European descent, we built genetic models to predict DNA methylation levels. After internal and external validation, we applied prediction models with satisfactory performance to the genetic data of 8,280 pancreatic cancer cases and 6,728 controls of European ancestry to investigate the associations of predicted methylation with pancreatic cancer risk. For associated CpGs, we compared their measured levels in pancreatic tumor versus benign tissue.Results:We identified 45 CpGs at nine loci showing an association with pancreatic cancer risk, including 15 CpGs showing an association independent from identified risk variants. We observed significant correlations between predicted methylation of 16 of the 45 CpGs and predicted expression of eight adjacent genes, of which six genes showed associations with pancreatic cancer risk. Of the 45 CpGs, we were able to compare measured methylation of 16 in pancreatic tumor versus benign pancreatic tissue. Of them, six showed differentiated methylation.Conclusions:We identified methylation biomarker candidates associated with pancreatic cancer using genetic instruments and added additional insights into the role of methylation in regulating gene expression in pancreatic cancer development.Impact:A comprehensive study using genetic instruments identifies 45 CpG sites at nine genomic loci for pancreatic cancer risk.
Early phase clinical studies of AR ‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
Welling, D. Bradley , Collier, Katharine A. , Burns, Sarah S. , Oblinger, Janet L. , Shu, Edina , Miles‐Markley, Beth A., Slone, H. Wayne, Neff, Brian A., Jackler, Robert K. , Mortazavi, Amir , Chang, Long‐Sheng , Mansouri, Alireza , Jackler, Robert K , Mansouri, Alireza , Hofmeister, Craig C. , Makary, Mina S. , Blakeley, Jaishri O. , Mansouri, Sheila

Mayo Clinic

Laryngoscope Investigative Otolaryngology | August 20, 2021 | Volume: 6 | Issue: 5 | Pages: 1008-1019

10.1002/lio2.643 | PMID 34667843 Get It

Abstract Objectives Two pilot studies of AR‐42, a pan‐histone deacetylase inhibitor, in human neurofibromatosis type 2 (NF2), vestibular schwannomas (VS), and meningiomas are presented. Primary endpoints included safety, and intra‐tumoral pharmacokinetics (PK) and pharmacodynamics (PD). Methods Pilot 1 is a subset analysis of a phase 1 study of AR‐42 in solid tumors, which included NF2 or sporadic meningiomas. Tumor volumes and treatment‐related adverse events (TRAEs) are reported (NCT01129193). Pilot 2 is a phase 0 surgical study of AR‐42 assessing intra‐tumoral PK and PD. AR‐42 was administered for 3 weeks pre‐operatively. Plasma and tumor drug concentrations and p‐AKT expression were measured (NCT02282917). Results Pilot 1: Five patients with NF2 and two with sporadic meningiomas experienced a similar incidence of TRAEs to the overall phase I trial. The six evaluable patients had 15 tumors (8 VS, 7 meningiomas). On AR‐42, tumor volume increased in six, remained stable in eight, and decreased in one tumor. The annual percent growth rate decreased in eight, remained stable in three, and increased in four tumors. Pilot 2: Four patients with sporadic VS and one patient with meningioma experienced no grade 3/4 toxicities. Expression of p‐AKT decreased in three of four VS. All tumors had higher AR‐42 concentrations than plasma. Conclusions AR‐42 is safe. Tumor volumes showed a mixed response, but most slowed growth. On a 40‐mg regimen, drug concentrated in tumors and growth pathways were suppressed in most tumors, suggesting this may be a well‐tolerated and effective dose. A phase 2 study of AR‐42 for NF2‐associated tumors appears warranted. Level of Evidence 1b, 4.
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
Francini, Edoardo , Ou, Fang‐Shu , Wolfe, Eric, O’Connor, Edward , Gydush, Gregory, Kelleher, Kaitlin M. , Bhatt, Rupal S. , Balk, Steven P. , Sweeney, Christopher J. , Adalsteinsson, Viktor A. , Taplin, Mary‐Ellen , Choudhury, Atish D. , Wolfe, Eric G, Balk, Steven , Choudhury, Atish D , Ou, Fang-Shu , Sweeney, Christopher , Rhoades, Justin , Ha, Gavin

Mayo Clinic

Cancers | August 12, 2021 | Volume: 13 | Issue: 16 | Pages: 4055

10.3390/cancers13164055 | PMID 34439209 Get It

There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to docetaxel or cabazitaxel for patients with mCRPC, using circulating cell-free DNA (cfDNA). Patients with ≥1 plasma sample drawn within 12 months before starting docetaxel (cohort A) or cabazitaxel (cohort B) for mCRPC were identified from the Dana–Farber Cancer Institute IRB approved database. Sparse whole genome sequencing was performed on the selected cfDNA samples and tumor fractions were estimated using the computational tool ichorCNA. We evaluated the association between ABCB1 amplification or other copy number alterations and primary resistance to docetaxel or cabazitaxel. Of the selected 176 patients, 45 samples in cohort A and 21 samples in cohort B had sufficient tumor content. No significant association was found between ABCB1 amplification and primary resistance to docetaxel (p = 0.58; odds ratio (OR) = 1.49) or cabazitaxel (p = 0.97; OR = 1.06). No significant association was found between exploratory biomarkers and primary resistance to docetaxel or cabazitaxel. In this study, ABCB1 amplification did not predict primary resistance to docetaxel or cabazitaxel for mCRPC. Future studies including ABCB1 amplification in a suite of putative biomarkers and a larger cohort may aid in drawing definitive conclusions.
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Snyder, Rebecca A. , Le‐Rademacher, Jennifer , Dodge, Andrew , Chang, George J. , Innocenti, Federico , Blanke, Charles D. , Lenz, Heinz‐Josef, Polite, Blasé N. , Le-Rademacher, Jennifer G , Zemla, Tyler J, Polite, Blasé N , He, Jun , Ou, Fang‐Shu , Zemla, Tyler , Paskett, Electra D. , Lenz, Heinz‐Josef , Venook, Alan P. , Snyder, Rebecca A

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 20 | Pages: 3801-3808

10.1002/cncr.33649 | PMID 34374082 Get It

BackgroundThe objective of this study was to evaluate the association between self‐identified race and overall survival (OS), progression‐free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.MethodsPatients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model.ResultsIn total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73‐1.16), PFS (HR, 0.97; 95% CI, 0.78‐1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65‐1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02‐1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18‐1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22‐2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24‐0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72‐1.65).ConclusionsNo difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.Lay Summary Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer‐specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression‐free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
Khan, Aliya , Rubin, Mishaela R. , Vokes, Tamara , Ahmed, Intekhab, Hofbauer, Lorenz C. , Marcocci, Claudio , Palermo, Andrea , Eriksen, Erik Fink , Brod, Meryl , Markova, Denka, Pihl, Susanne, Mourya, Sanchita, Karpf, David, Shu, Aimee D , Clarke, Bart, Marcocci, Claudio , Palermo, Andrea , Shu, Aimee D , Hofbauer, Lorenz C , Rejnmark, Lars , Schwarz, Peter , Clarke, B.L. , Pagotto, Uberto , Smith, Alden Raymond

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 4, 2021 | Volume: 107 | Issue: 1 | Pages: e372-e385

10.1210/clinem/dgab577 | PMID 34347093 Get It

Abstract Context Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. Objective This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism. Methods This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 µg PTH(1-34)/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 µg PTH[1-34]/day). Results By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D = 0 μg/day and calcium [Ca] ≤ 500 mg/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg/24h to 178 mg/24h by Week 26 (n = 44) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events. Conclusion TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Gile, Jennifer , Ou, Fang‐Shu , Mahipal, Amit , Larson, Joseph J. , Mody, Kabir , Jin, Zhaohui , Hubbard, Joleen M. , Hálfdánarson, Þorvarður R. , Alberts, Steven R. , Jatoi, Aminah , Smoot, Rory L. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Gile, Jennifer Jane , Hubbard, Joleen , Halfdanarson, Thorvardur R , McWilliams, Robert R , Ma, Wen Wee , Ilyas, Sumera, Roberts, Lewis R , Borad, Mitesh J , Smoot, Rory L , Mahipal, Amit , Alberts, Steven R , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Jin, Zhaohui , McWilliams, Robert R. , Wee, Wen , Ilyas, Sumera I. , Gores, Gregory J. , Borad, Mitesh J. , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 28, 2021 | Volume: No volume available | Issue: 5 | Pages: 1228-1240

10.1200/po.21.00064 | PMID 34778691 Get It

PURPOSECholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor receptor ( FGFR) alterations, which occurs in approximately 15%-20% of intrahepatic CCAs. Herein, we describe the FGFR inhibitor (FGFRi)-associated treatment toxicity and cancer-specific outcomes from a multicenter single-institution cohort.METHODSThis is a retrospective study of patients with CCA and known FGFR alterations treated with FGFRi. We describe the toxicity and efficacy in patients treated at Mayo Clinic between January 2010 and December 2020.RESULTSOur group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi. The most common grade 1 or higher adverse events for all patients included fatigue (92%), AST elevations (78%), anemia (80%), decreased platelet count (63%), and hyperphosphatemia (74%). Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Females had significantly longer progression-free survival at 6.9 months (95% CI, 5.2 to 11.8) on FGFRi compared with males at 4.9 months (95% CI, 2.8 to not estimable; P = .038).CONCLUSIONFGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.
Autophagy and Tau Protein
Hamano, Tadanori , Enomoto, Soichi, Shirafuji, Norimichi, Ikawa, Masamichi , Yamamura, Osamu , Yen, Shu-Hui, Nakamoto, Yasunari

Mayo Clinic

International Journal of Molecular Sciences | July 12, 2021 | Volume: 22 | Issue: 14 | Pages: 7475

10.3390/ijms22147475 | PMID 34299093 Get It

Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer’s disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. This suggests that autophagy function is disturbed in AD. We used a neuronal cellular model of tauopathy (M1C cells), which harbors wild type tau (4R0N), to assess the effects of the lysosomotrophic agent NH4Cl, and autophagy inhibitors chloroquine and 3 methyladenine (3MA). It was found that chloroquine, NH4Cl and 3MA markedly increased tau accumulation. Thus, autophagy lysosomal system disturbances disturbed the degradation mechanisms of tau protein. Other studies also revealed that tau protein, including aggregated tau, is degraded via the autophagy lysosome system. Phosphorylated and C terminal truncated tau were also reported to disturb autophagy function. As a therapeutic strategy, autophagy upregulation was suggested. Thus far, as autophagy modulators, rapamycin, mTOCR1 inhibitor and its analogues, lithium, metformin, clonidine, curcumin, nicotinamide, bexaroten, and torehalose have been proposed. As a therapeutic strategy, autophagic modulation may be the next target of AD therapeutics.
Improved Brain MR Imaging from a Compact, Lightweight 3T Scanner with High‐Performance Gradients
Camerucci, Emanuele , Trzasko, Joshua D. , Gray, Erin M. , Bernstein, Matt A. , Cogswell, Petrice M. , Shu, Yunhong , Foo, Thomas , Bernstein, Matt A , Cogswell, Petrice M , Foo, Thomas K F , Campeau, Norbert G. , Huston, John

Mayo Clinic

Journal of Magnetic Resonance Imaging | June 29, 2021 | Volume: 55 | Issue: 1 | Pages: 166-175

10.1002/jmri.27812 | PMID 34184362 Get It

BackgroundA low‐cryogen, compact 3T (C3T) MRI scanner with high‐performance gradients capable of simultaneously achieving 80 mT/m gradient amplitude and 700 T/m/second slew rate has been in use to study research patients since March 2016 but has not been implemented in the clinical practice.PurposeTo compare head MRI examinations obtained with the C3T system and a conventional whole‐body 3T (WB3T) scanner in seven parameters across five commonly used brain imaging sequences.Study TypeProspective.SubjectsThirty patients with a clinically indicated head MRI.Sequence 3T; T1 FLAIR, T1 MP‐RAGE, 3D T2 FLAIR, T2 FSE, and DWI.AssessmentAll patients tolerated the scans well. Three board‐certified neuroradiologists scored the comparative quality of C3T and WB3T images in blinded fashion using a five‐point Likert scale in terms of: signal‐to‐noise ratio, lesion conspicuity, motion artifact, gray/white matter contrast, cerebellar folia, susceptibility artifact, and overall quality.Statistical TestLeft‐sided, right‐sided, and two‐sided Wilcoxon signed rank test; Fisher's method. A P value <0.05 was considered statistically significant.ResultsThe C3T system performed better than the WB3T in virtually all comparisons, except for motion artifacts for the T1 FLAIR and T1 MP‐RAGE sequences, where the WB3T system was deemed better. When combining all sequences together, the C3T system outperformed the WB3T system in all image quality parameters evaluated, except for motion artifact (P = 0.13).Data ConclusionThe C3T scanner provided better overall image quality for all sequences, and performed better in all individual categories, except for motion artifact on the T1 FLAIR and T1 MP‐RAGE.Level of Evidence2Technical Efficacy Stage1
Transcriptional landscape of human microglia reveals robust gene expression signatures that implicates age, sex and APOE-related immunometabolic pathway perturbations
Carnwath, Troy , Wang, Xue , Allen, Mariet , Lincoln, Sarah, Lewis‐Tuffin, Laura J. , Quicksall, Zachary , Lin, Shu, Tutor‐New, Frederick Q, Ho, Charlotte C.G. , Min, Yuhao , Malphrus, Kimberly G., Nguyen, Thuy , Martin, Elizabeth, Al‐kharboosh, Rawan , Chaichana, Kaisorn L. , Wharen, Robert E. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Ertekin‐Taner, Nilüfer , Guerrero-Cazares, Hugo , Patel, Tulsi , Garcia, César A. , Grewal, Sanjeet S.

Mayo Clinic

No container title available | June 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-523348/v1 Get It

Abstract Microglia have fundamental roles in health and disease, however effects of age, sex and genetic factors on human microglia have not been fully explored. We applied bulk and single cell approaches to comprehensively characterize human microglia transcriptomes and their associations with age, sex and APOE . We identified a novel microglial signature, characterized its expression in bulk data from 1,306 brain samples across 6 regions and in single cell microglia transcriptome. We discovered microglial co-expression network modules associated with age, sex and APOE -ε4 that are enriched for lipid and carbohydrate metabolism genes. Integrated analyses of modules with single cell transcriptomes revealed significant overlap between age-associated module genes and both pro-inflammatory and disease-associated microglial clusters. These modules and clusters harbor known neurodegenerative disease genes including APOE, PLCG2 and BIN1 . These data represent a well-characterized human microglial transcriptome resource; and highlight age, sex and APOE -related microglial immunometabolism perturbations with potential relevance in neurodegeneration.